Influence of Different Light Dose on the Adverse Effect of Swallowing for Esophageal Carcinoma
A Phase III Randomized Controlled Study of the Effect of Different Light Doses on Adverse Outcomes of Swallowing in Esophageal Cancer
調査の概要
詳細な説明
Background: Photodynamic therapy (PDT) is one of the effective means for the control of esophageal stenosis in advanced esophageal cancer, among which the dose intensity of laser irradiation is one of the factors affecting the efficacy. This study aims to pursue the appropriate dose of light.
Aim: To compare the efficacy and safety of two groups of different laser irradiation doses for advanced esophageal cancer and esophageal stricture.
Methods: Fifty-seven patients were recruited for this study and randomly divided into two groups: single irradiation group and reirradiation group.Single irradiation group: 46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Double irradiation group: 46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
Primary endpoints: ORR rates at 1 and 3 months, the quality of life
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Shegan Gao, MD, PhD
- 電話番号:18638859977
- メール:gsg112258@163.com
研究連絡先のバックアップ
- 名前:Tanyou Shan, MD, PhD
- 電話番号:18537976669
- メール:shantanyoudoctor@163.com
研究場所
-
-
Henan
-
Luoyang、Henan、中国、471003
- The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- esophagus cancer
- 18-80 years old
- grade 3-4 dysphagia (Stoller classification)
- Non-eradicative second-line treatment
Exclusion Criteria:
- Ulcerative tumor
- Esophageal stenosis caused by radiotherapy
- Survival is less than 3 months
- Patients known to be allergic to photosensitizers
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:single irradiation group
46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
|
46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
|
|
アクティブコンパレータ:Double irradiation group
46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
|
46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
1 month objective response rate
時間枠:1 month after photodynamic irradiation
|
Grade 3-4 dysphagia accounted
|
1 month after photodynamic irradiation
|
|
3 month objective response rate
時間枠:3 month after photodynamic irradiation
|
Grade 3-4 dysphagia accounted
|
3 month after photodynamic irradiation
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
3 month Quality of Life score
時間枠:3 month after photodynamic irradiation
|
3 month after photodynamic irradiation
|
協力者と研究者
捜査官
- スタディチェア:Shegan Gao, MD, PhD、The First Affiliated Hospital of Clinical Medicine of Henan University of Science and Technology
- スタディディレクター:Tanyou Shan, MD, PhD、The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- 主任研究者:Caihong Dong, MD, PhD、The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- 主任研究者:Wanying Li, MD、The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- 主任研究者:Jiachun Sun, MD, PhD、The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- 主任研究者:Mengxi Zhang, MD, PhD、The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
- 主任研究者:Xiaozhi Yuan, MD, PhD、The First Affiliated Hospital and Clinical Medicine of Henan University of Science and Technology
出版物と役立つリンク
一般刊行物
- Zeng R, Liu C, Li L, Cai X, Chen R, Li Z. Clinical Efficacy of HiPorfin Photodynamic Therapy for Advanced Obstructive Esophageal Cancer. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820930335. doi: 10.1177/1533033820930335.
- Yoon HY, Cheon YK, Choi HJ, Shim CS. Role of photodynamic therapy in the palliation of obstructing esophageal cancer. Korean J Intern Med. 2012 Sep;27(3):278-84. doi: 10.3904/kjim.2012.27.3.278. Epub 2012 Sep 1.
- Liu H, Liu Y, Wang L, Ruan X, Wang F, Xu D, Zhang J, Jia X, Liu D. Evaluation on Short-Term Therapeutic Effect of 2 Porphyrin Photosensitizer-Mediated Photodynamic Therapy for Esophageal Cancer. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819831989. doi: 10.1177/1533033819831989.
- Lee HH, Choi MG, Hasan T. Application of photodynamic therapy in gastrointestinal disorders: an outdated or re-emerging technique? Korean J Intern Med. 2017 Jan;32(1):1-10. doi: 10.3904/kjim.2016.200. Epub 2017 Jan 1.
- Yano T, Minamide T, Takashima K, Nakajo K, Kadota T, Yoda Y. Clinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer. J Clin Med. 2021 Jun 24;10(13):2785. doi: 10.3390/jcm10132785.
- National Health Commission Of The People's Republic Of China. Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version). Chin J Cancer Res. 2019 Apr;31(2):223-258. doi: 10.21147/j.issn.1000-9604.2019.02.01. No abstract available.
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
食道がんの臨床試験
-
Novartis Pharmaceuticals終了しましたメラノーマ | 高度なEGFR変異体非小さな細胞肺cancer(NSCLC) | KRAS G12変異NSCLC | 食道扁平上皮がん(SCC) | ヘッド/ネックSCC | 進行した胃腸間質腫瘍(GIST) | 進行したNRAS/BRAFT WT皮膚黒色腫アメリカ, 台湾, オランダ, カナダ, スペイン, シンガポール, イタリア, 日本, 韓国
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ
single irradiationの臨床試験
-
Chinese University of Hong Kongまだ募集していません
-
DD-Hippero s.r.o.PharmTest s.r.o.; Prague Clinical Services s.r.o.完了
-
University of OxfordUniversity of Copenhagen; Zimmer Biometわからない
-
University of Sao PauloUniversidade Federal de Sao Carlos完了
-
Gilead Sciences完了